<DOC>
	<DOCNO>NCT02638922</DOCNO>
	<brief_summary>Objective To evaluate phenotypic characteristic diagnose large cohort 304 consecutive girl refer due tall stature . Furthermore , evaluate effect oral administration 17β-estradiol predict adult height constitutionally tall statured girl . Design A single-centre retrospective observational study 304 girl evaluate due tall stature 1993 2013 . Setting Tertiary referral centre pediatric endocrinology . Participants A total 304 girl evaluate tall stature 39 ( 13 % ) exclude due miss data , reclassification , overgrowth syndrome associated comorbidities . Another 58 ( 19 % ) girl fulfil auxological criterion constitutionally tall stature ( CTS ) , result total 207 ( 68 % ) girl eligible analysis . Main Outcome Measures The effect oral treatment 17β-estradiol height , predict adult height ( PAH ) , final height circulate hormone constitutional tall statured girl .</brief_summary>
	<brief_title>Evaluation Treatment Tall Statured Girls</brief_title>
	<detailed_description>17α-ethinylestradiol ( EE2 ) treatment extreme tall stature become increasingly debated controversial . In Sweden , percutaneous epiphysiodesis operation suggest alternative EE2 treatment . An alternative clinical practise introduce 20 year ago , early treatment oral administration natural estrogen ( 17β-estradiol ( E2 ) ) introduce order initiate ensure rapid progression puberty ( epiphyseal closure ) tall statured girl . A retrospective 20-year single center experience include evaluation 304 tall statured girl possible clinical effect oral administration E2 . Subjects method Patients The patient population consist girl refer tall stature overgrowth syndrome ( ICD10 34.4 , ICD10 DE874 , DQ970 , DQ873A , DQ873B ) Department Growth Reproduction Rigshospitalet Copenhagen , Denmark , 20-years period ( 1993 2013 ) . A total 304 patient identify , diagnose re-evaluated part present study . Clinical data medical history Medical history obtain use structured review patient record file . Clinical data pubertal development obtain patient visit . Puberty evaluate inspection palpation breast pubic hair accord Marshall Tanner . A wall-mounted stadiometer ( Holtain Ltd. , Crymych , United Kingdom ) use measure stand height near 0.1 cm . The girl weigh digital electronic scale ( Seca delta , model 707 ; Seca , Hamburg , Germany ) precision 0.1 kg wear light clothing shoe . BMI calculate weight ( kg ) divide height ( m2 ) . The Danish growth reference publish Tinggaard et al . use study . Boneage ( BA ) calculate accord method Greulich Pyle ( GP ) use manual reading 1993-2008 ( n=368 ) , automate BA estimation 2008-2013 ( n=378 ) . Target height calculate sum mother 's father 's height ( cm ) minus 13 cm , divide 2 . Predicted Adult Height ( PAH ) calculate use BoneXpert . 17β-Estradiol treatment The decision initiate treatment E2 determine individually , make physician together patient parent , depend height SDS , age , PAH target height . Oral E2 administer increase dos depend age pubertal stage . The starting dos range 0.2 mg E2 4 mg E2 . The speed dose increment depend individual girl ( age , bone BA , maturity , pubertal stage PAH ) . The treatment consist 17β-estradiol supplemented norethisteronacetat 1-2 year E2 , first menstrual bleeding . Oral E2 treatment administer form Trisekvens® ( Novo Nordisk Scandinavia AB , Copenhagen , Denmark ) , Trisekvens Forte® ( Novo Nordisk Scandinavia AB , Copenhagen , Denmark ) and/or Femanest® ( Sandoz A/S , Copenhagen , Denmark ) . Clinical biochemical value record baseline year thereafter . The treatment generally terminate X-ray show closed epiphyseal line final near-final ( &lt; 2 cm/year ) height . Laboratory analysis Blood sample draw antecubital vein 8 AM 1 PM non-fasting state . Blood sample clot centrifuge , serum store -20° Celsius hormone analyse perform . Serum follicle-stimulating hormone ( FSH ) luteinising hormone ( LH ) measure time-resolved immunofluorometric assay ( Delfia , Wallac , Turku , Finland ) . The detection limit ( dL ) FSH LH 0.06 0.05 IU/l , respectively . Intra- interassay coefficient variation ( CV ) &lt; 5 % gonadotropin assay . Testosterone measure radioimmunoassay ( RIA ) ( Coat-a-count , Diagnostic Products Corporation , Los Angeles , CA ) dL 0.23 nmol/L intra- interassay CV &lt; 10 % . Serum sex hormone-binding globulin ( SHBG ) measure time-resolved immunofluorometric assay ( Delfia , Wallac , Turku , Finland ) dL 0.20 nmol/l , intra- interassay CVs 5.8 % 6.4 % , respectively . Serum insulin-like growth factor I ( IGF-I ) measure use highly sensitive in-house RIA previously describe Juul et al . The intra- interassay CV 3.9 % 8.7 % , respectively . From 2008 IGF-I level determine conventional immunoassay ( IMMULITE 2000 IGF-1 ; Siemens Healthcare Diagnostics , Los Angeles , CA , USA ) automate IMMULITE 2000 ( Siemens ) . The CV le 4 % 9 % , respectively . Serum insulin-like growth factor-binding protein 3 ( IGFBP-3 ) measure RIA , previously describe Blum et al . The intraassay CV 2.4 % interassay CV 10.7 % . Between 1993 2013 , serum inhibin B measure use one two double antibody enzyme immunometric assay ( Inhibin B DSL Oxford Bio-Innovation Inhibin B ) , dL 20 pg/ml intra- interassay CV &lt; 16 % . Estradiol measure RIA ( Pantex , Santa Monica , CA ; 1998 distribute Immuno Diagnostic Systems , Bolton , UK ) dL 18 pmol/L , intra- interassay CVs &lt; 8 % &lt; 13 % , respectively . Only assay IGF-I change 20-year study period , compare two assay rigorously ensure yielded similar result change assay . Statistical analysis Data display median interquartile range ( 25th ; 75th percentile ) and/or range ( min - max ) . Results treatment effect IGF-I ( SD ) display mean ± SD . Hormone value dL assay assign value correspond dL/2 . The Mann-Whitney U test student 's test use determine significance compare clinical , auxological , laboratory data group , student 's t-test use compare effect treatment within group girl treat oral E2 . All statistical analysis perform use SPSS software ( IBM Corporation , Armonk , NY , version 22 ) .</detailed_description>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Trisequens</mesh_term>
	<criteria>tall stature ( height &gt; 2 SD )</criteria>
	<gender>Female</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>